Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Amneal Pharmaceuticals (AMRX)

Amneal previews Q2 2025: revenue $720 million to $730 million, up about 3%

Positive Impact 3 of 5 earnings Written later

Amneal Pharmaceuticals released unaudited preliminary second-quarter 2025 results, with net revenue of $720 million to $730 million and adjusted EBITDA of $180 million to $185 million, both up versus the same period in 2024. The company said it expects to meet or exceed its full-year 2025 guidance, and the figures may change before the final results due August 5, 2025. Separately, director Emily Peterson Alva resigned from the Board and its Audit Committee, effective immediately, which the company said was not due to any disagreement.

Key points

  • Net revenue of $720 million to $730 million, up about 3% from the same period in 2024
  • Adjusted EBITDA of $180 million to $185 million, up about 13%; income before income taxes of $45 million to $56 million versus $20 million a year earlier
  • Gross leverage fell to 3.8x and net leverage to 3.7x as of June 30, 2025, from 4.1x and 3.9x at December 31, 2024
  • Emily Peterson Alva, an Amneal Group designee, resigned from the Board on July 16, 2025; the Amneal Group's board designation right was reduced from six to five

The filing

CompanyAmneal Pharmaceuticals (AMRX)
Form8-K, current report
Filed with the SECJul 21, 2025, 7:41 AM ET
Accession number0001723128-25-000033

Items reported: 2.02 Results of Operations5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 21, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.